What the current Wegovy label says
The current Wegovy label is direct on this point. It says semaglutide may cause fetal harm. For patients using Wegovy for weight reduction or cardiovascular-risk reduction, the label says to discontinue the drug when pregnancy is recognized.
That is the correct anchor for this topic. A strong page should lead with the exact regulatory warning frame instead of drifting into exaggerated claims or pretending the page can replace obstetric or prescribing guidance.
References For This Section
Planned pregnancy and the 2-month timing issue
The planning question matters almost as much as exposure during pregnancy. The current label says to discontinue Wegovy at least 2 months before a planned pregnancy because semaglutide has a long half-life. MedlinePlus gives similar advice for patients planning pregnancy.
That is why people often search this topic before conception rather than after. The practical value of the page is to explain the timing clearly and push people toward clinician guidance instead of leaving them with half-remembered social-media advice.
References For This Section
What to document if exposure happened
Write down the product used, the dose, when the last dose was taken, when pregnancy was recognized, who was contacted, and what advice was given. If there were medication changes or follow-up visits, keep those records and dates.
That documentation matters for medical care first. If there is ever a later discussion of what happened, a clean timeline is much more useful than trying to reconstruct exposure details from memory alone.
References For This Section